CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

Cancer shared this article with you from Inoreader CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD. Via MedWorm Cancer & Oncology Clinical Trials Condition:   CLL Interventions:   Drug: ibrutinib, venetoclax, obinutuzumab;   Drug: ibrutinib, venetoclax Sponsors:   Stichting Hemato-Oncologie voor Volwassenen Nederland;   Nordic Lymphoma Group Not yet recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.